(signalling 
,1)
(degradation,1)
(than,5)
(staining,1)
(gene,2)
((28 04%) 
Meta-analysis,1)
(drug-resistant,1)
(improve,4)
(include,1)
(presentation,1)
(kappa-B,1)
(46,1)
(intervention,5)
(several,5)
(we,10)
(multimodal,1)
(affected,1)
((CA,1)
(who,7)
(87%,1)
(tissue,,2)
(ZJU-1127,1)
(meta-analysis,2)
(responses,1)
(shown,3)
(contrast,2)
(immunologic,1)
(recurrence,6)
(caused,1)
(response 
Mucin,1)
(western,3)
(double,1)
(patients,,2)
(exchange,1)
(trials 
The,1)
(aesthetic,1)
(free,2)
(preoperative,4)
(cognitive,1)
(tumorigenicity,1)
(1 26,,1)
(granulosus,,1)
(disrupting,1)
(isoform,1)
(assessment,3)
(alendronate,,1)
(modalities,2)
(chemotherapeutic,2)
(acts,1)
(hepatitis,,1)
(supplying,1)
(values,2)
(cancer 
The,3)
(cyst,1)
(survival,14)
(subpopulation,1)
(basal-like,1)
(circumstances,1)
(literature,,1)
(2,,1)
(0 950,1)
(but,12)
(inhibition,3)
(Basal/human,1)
(showed,11)
(phase,4)
(Fe+,2)
(dynamics,3)
(versus,1)
(strategies ,1)
(disease-free,1)
(extracts,1)
(mitochondrial,2)
((ABTS),1)
(necessary,1)
(had,10)
(even,2)
(enhancement,7)
(ER-positive/human,1)
(proteins,6)
(extranuclear,1)
(ligases,1)
(finding ,1)
(sufficient,1)
(lithiasis,,1)
(methods,3)
(they,1)
(migration,,1)
(likely,2)
(activity 
For,1)
(chemotherapy 
As,1)
(cancer,,8)
(Italy) 
All,1)
(implied,1)
(lungs 
Notably,,1)
(benefit,2)
(feasibility 
Patient,1)
(10,1)
(2015,,1)
(ultrastructure;,1)
(prior,5)
(medium,1)
(according,4)
(immunotherapy 
Display,1)
(parameters 
Moreover,,1)
(phytochemicals,1)
(hazards,1)
(breast,106)
(G2,1)
((range,1)
(I,1)
(molecules,1)
(evaluation 
The,1)
(ESR1,7)
(abnormal,1)
(cells ,1)
(mediated,2)
((OVs),1)
(months,1)
(z,,1)
(cancer 
Mammography,1)
(hydatid,2)
(NSM,1)
(contrast-enhanced,2)
(mice 
Here,,1)
(tumorous,1)
(benefits,1)
(decrease,1)
(vitro 
An,1)
(activities,3)
(proliferation,9)
(microenvironment,1)
(variation,1)
(crucial,1)
(increased 
The,1)
(metrics,1)
(cosmesis 
Our,1)
(preferences,1)
(RANKL,1)
(nu),1)
(positive,3)
(therapy 
,1)
(CT,4)
(treatment,,5)
(expression 
Their,1)
(ERα,6)
(worldwide 
New,1)
(additive,1)
(anti-proliferative,1)
(7%,,1)
(differentiation,,1)
(ligand,2)
(member,1)
(plasma,11)
(blot,2)
(pallidus),,1)
(designing,1)
(side,1)
(remains,5)
(P=0 01),,1)
(without,3)
(parenchyma,,1)
(biology,1)
(cause,4)
(OBCS,1)
(untreated,1)
(latest,1)
(h,,2)
(mouse,2)
(loop,2)
(influence,1)
(67,1)
(silica,1)
(oral,4)
(cytometry,1)
(increasingly,1)
(into,8)
(resonance,2)
(0 0001),1)
(c-Myc,,1)
(mutation;,1)
(Wechsler,1)
(receptors 
,1)
(therapies,,2)
(effectively,2)
(downregulating,2)
(therapies 
In,1)
(continuous,1)
(fractionation,2)
(1 17-1 66;,1)
(validated,4)
(December,1)
(compared 
Agreement,1)
(drives,1)
((cumulative,1)
((n = 22) × study,1)
(depends,1)
(145,1)
(7,1)
(inhibit,3)
(serious,1)
(protein,6)
(structure 
With,1)
(assay 
The,2)
(blocked,2)
(1 36-2 01;,1)
(intraclass,1)
(receptor-positive/human,1)
(tapeworm,1)
(Orthosiphon,4)
(chemokine,2)
(women,19)
(antimicrobial,,1)
(controversial 
We,1)
(BRCA,1)
((ZJU-0327,,1)
(subtype 
Taken,1)
(reconstruction,1)
(identify,1)
(investigation,3)
(deliver 
Regular,1)
((BC),1)
(cutoff,,1)
((OBCS),1)
(malignant,2)
(IR-A,1)
(positive,,2)
(delivered,1)
(construct,1)
(work,4)
(effectiveness,1)
(low 
Preoperative,1)
(valuable,2)
(cycle,,2)
(subset,1)
(stratification,1)
(lacking,1)
((67 9,1)
(prognostic,,1)
(data 
Descriptive,1)
(HR,4)
(simulated,1)
(EgKI-1-treated,1)
(0 009),1)
(revealed,5)
(response,3)
(2 × 2,1)
(models,2)
(decline,2)
